Literature DB >> 15564492

Long-term excretion of vaccine-derived poliovirus by a healthy child.

Javier Martín1, Kofi Odoom, Gráinne Tuite, Glynis Dunn, Nicola Hopewell, Gill Cooper, Catherine Fitzharris, Karina Butler, William W Hall, Philip D Minor.   

Abstract

A child was found to be excreting type 1 vaccine-derived poliovirus (VDPV) with a 1.1% sequence drift from Sabin type 1 vaccine strain in the VP1 coding region 6 months after he was immunized with oral live polio vaccine. Seventeen type 1 poliovirus isolates were recovered from stools taken from this child during the following 4 months. Contrary to expectation, the child was not deficient in humoral immunity and showed high levels of serum neutralization against poliovirus. Selected virus isolates were characterized in terms of their antigenic properties, virulence in transgenic mice, sensitivity for growth at high temperatures, and differences in nucleotide sequence from the Sabin type 1 strain. The VDPV isolates showed mutations at key nucleotide positions that correlated with the observed reversion to biological properties typical of wild polioviruses. A number of capsid mutations mapped at known antigenic sites leading to changes in the viral antigenic structure. Estimates of sequence evolution based on the accumulation of nucleotide changes in the VP1 coding region detected a "defective" molecular clock running at an apparent faster speed of 2.05% nucleotide changes per year versus 1% shown in previous studies. Remarkably, when compared to several type 1 VDPV strains of different origins, isolates from this child showed a much higher proportion of nonsynonymous versus synonymous nucleotide changes in the capsid coding region. This anomaly could explain the high VP1 sequence drift found and the ability of these virus strains to replicate in the gut for a longer period than expected.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15564492      PMCID: PMC533926          DOI: 10.1128/JVI.78.24.13839-13847.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  43 in total

1.  Interaction of the poliovirus receptor with poliovirus.

Authors:  Y He; V D Bowman; S Mueller; C M Bator; J Bella; X Peng; T S Baker; E Wimmer; R J Kuhn; M G Rossmann
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

2.  Evolution of circulating wild poliovirus and of vaccine-derived poliovirus in an immunodeficient patient: a unifying model.

Authors:  G V Gavrilin; E A Cherkasova; G Y Lipskaya; O M Kew; V I Agol
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

3.  Circulation of endemic type 2 vaccine-derived poliovirus in Egypt from 1983 to 1993.

Authors:  Chen-Fu Yang; Tary Naguib; Su-Ju Yang; Eman Nasr; Jaume Jorba; Nahed Ahmed; Ray Campagnoli; Harrie van der Avoort; Hiroyuki Shimizu; Tetsuo Yoneyama; Tatsuo Miyamura; Mark Pallansch; Olen Kew
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

4.  Evolution of the Sabin strain of type 3 poliovirus in an immunodeficient patient during the entire 637-day period of virus excretion.

Authors:  J Martín; G Dunn; R Hull; V Patel; P D Minor
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

5.  Acute flaccid paralysis associated with circulating vaccine-derived poliovirus--Philippines, 2001.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2001-10-12       Impact factor: 17.586

Review 6.  Characteristics of poliovirus strains from long-term excretors with primary immunodeficiencies.

Authors:  P Minor
Journal:  Dev Biol (Basel)       Date:  2001

7.  Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus.

Authors:  Olen Kew; Victoria Morris-Glasgow; Mauricio Landaverde; Cara Burns; Jing Shaw; Zacarías Garib; Jean André; Elizabeth Blackman; C Jason Freeman; Jaume Jorba; Roland Sutter; Gina Tambini; Linda Venczel; Cristina Pedreira; Fernando Laender; Hiroyuki Shimizu; Tetsuo Yoneyama; Tatsuo Miyamura; Harrie van Der Avoort; M Steven Oberste; David Kilpatrick; Stephen Cochi; Mark Pallansch; Ciro de Quadros
Journal:  Science       Date:  2002-03-14       Impact factor: 47.728

8.  Nucleotide variation in Sabin type 2 poliovirus from an immunodeficient patient with poliomyelitis.

Authors:  Gabriele Buttinelli; Valentina Donati; Stefano Fiore; Jill Marturano; Alessandro Plebani; Paolo Balestri; Anna Rosa Soresina; Rossella Vivarelli; Francis Delpeyroux; Javier Martin; Lucia Fiore
Journal:  J Gen Virol       Date:  2003-05       Impact factor: 3.891

9.  Long-term circulation of vaccine-derived poliovirus that causes paralytic disease.

Authors:  Elena A Cherkasova; Ekaterina A Korotkova; Maria L Yakovenko; Olga E Ivanova; Tatyana P Eremeeva; Konstantin M Chumakov; Vadim I Agol
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

10.  Recombinant vaccine-derived poliovirus in Madagascar.

Authors:  Dominique Rousset; Mala Rakoto-Andrianarivelo; Richter Razafindratsimandresy; Bakolalao Randriamanalina; Sophie Guillot; Jean Balanant; Philippe Mauclère; Francis Delpeyroux
Journal:  Emerg Infect Dis       Date:  2003-07       Impact factor: 6.883

View more
  19 in total

1.  Correlation of mutations and recombination with growth kinetics of poliovirus vaccine strains.

Authors:  V Pliaka; Z Kyriakopoulou; D Tsakogiannis; I G A Ruether; C Gartzonika; S Levidiotou-Stefanou; A Krikelis; P Markoulatos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-09-05       Impact factor: 3.267

2.  Retrospective characterization of a vaccine-derived poliovirus type 1 isolate from sewage in Greece.

Authors:  Evaggelos Dedepsidis; Zaharoula Kyriakopoulou; Vaia Pliaka; Christine Kottaridi; Eugenia Bolanaki; Stamatina Levidiotou-Stefanou; Dimitri Komiotis; Panayotis Markoulatos
Journal:  Appl Environ Microbiol       Date:  2007-09-07       Impact factor: 4.792

3.  Calibration of multiple poliovirus molecular clocks covering an extended evolutionary range.

Authors:  Jaume Jorba; Ray Campagnoli; Lina De; Olen Kew
Journal:  J Virol       Date:  2008-02-20       Impact factor: 5.103

4.  Isolation of sabin-like polioviruses from wastewater in a country using inactivated polio vaccine.

Authors:  Sebastian Zurbriggen; Kurt Tobler; Carlos Abril; Sabine Diedrich; Mathias Ackermann; Mark A Pallansch; Alfred Metzler
Journal:  Appl Environ Microbiol       Date:  2008-07-18       Impact factor: 4.792

5.  Impact of exogenous sequences on the characteristics of an epidemic type 2 recombinant vaccine-derived poliovirus.

Authors:  Franck B Riquet; Claire Blanchard; Sophie Jegouic; Jean Balanant; Sophie Guillot; Marie-Anne Vibet; Mala Rakoto-Andrianarivelo; Francis Delpeyroux
Journal:  J Virol       Date:  2008-06-25       Impact factor: 5.103

6.  Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs).

Authors:  Radboud J Duintjer Tebbens; Mark A Pallansch; Jong-Hoon Kim; Cara C Burns; Olen M Kew; M Steven Oberste; Ousmane M Diop; Steven G F Wassilak; Stephen L Cochi; Kimberly M Thompson
Journal:  Risk Anal       Date:  2013-03-07       Impact factor: 4.000

7.  Intratypic recombination among lineages of type 1 vaccine-derived poliovirus emerging during chronic infection of an immunodeficient patient.

Authors:  Chen-Fu Yang; Hour-Young Chen; Jaume Jorba; Hui-Chih Sun; Su-Ju Yang; Hsiang-Chi Lee; Yhu-Chering Huang; Tzou-Yien Lin; Pei-Jer Chen; Hiroyuki Shimizu; Yorihiro Nishimura; Andi Utama; Mark Pallansch; Tatsuo Miyamura; Olen Kew; Jyh-Yuan Yang
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

Review 8.  New generation of inactivated poliovirus vaccines for universal immunization after eradication of poliomyelitis.

Authors:  Konstantin Chumakov; Ellie Ehrenfeld
Journal:  Clin Infect Dis       Date:  2008-12-15       Impact factor: 9.079

9.  Shedding of vaccine viruses with increased antigenic and genetic divergence after vaccination of newborns with monovalent type 1 oral poliovirus vaccine.

Authors:  Sabine van der Sanden; Mark A Pallansch; Jan van de Kassteele; Nasr El-Sayed; Roland W Sutter; Marion Koopmans; Harrie van der Avoort
Journal:  J Virol       Date:  2009-06-10       Impact factor: 5.103

10.  In vivo ablation of type I interferon receptor from cardiomyocytes delays coxsackieviral clearance and accelerates myocardial disease.

Authors:  Nadine Althof; Stephanie Harkins; Christopher C Kemball; Claudia T Flynn; Mehrdad Alirezaei; J Lindsay Whitton
Journal:  J Virol       Date:  2014-02-26       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.